Heterogeneity of Envelope Molecules Shown by Different Sensitivities to Anti-V3 Neutralizing Antibody and CXCR4 Antagonist Regulates the Formation of Multiple-Site Binding of HIV-1

Microbiology and Immunology

Volumn 48, Issue 4, 2004, Pages 357-365

  Harada, Shinji ^a   Yusa, Keisuke ^a   Maeda, Yosuke ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

gp120 heterogeneity; HIV 1; Multiple site binding; Neutralization

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY; T 140;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMBRANE BINDING; MOLECULE; NONHUMAN; REGULATORY MECHANISM; ROOM TEMPERATURE; VIRUS ENVELOPE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 1942421739     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2004.tb03517.x     Document Type: Article

References (35)

1. Armstrong, S.J., McInerney, T.L., McLain, L., Wahren, B., Hinkula, J., Levi, M., and Dimmock, N.J. 1996. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. J. Gen. Virol. 77: 2931-2941.
2. Berger, E.A. 1997. HIV entry and tropism: the chemokine receptor connection. AIDS 11 (suppl A): S3-S16.
3. Briggs, D.R., Tuttle, D.L., Sleasman, J.W., and Goodenow, M.M. 2000. Envelope V3 amino acid sequence predicts HIV-1 phenotype (coreceptor usage and tropism for macrophages). AIDS 14: 2937-2939.
4. Cecilia, D., Kewal Ramani, V.N., O'Leary, J., Volsky, B., Nyambi, P., Burda, S., Xu, S., Littman, D.R., and Zolla-Pazner, S. 1998. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J. Virol. 72: 6988-6996.
5. Clapham, P.R., and McKnight, A. 2002. Cell surface receptors, virus entry and tropism of primate lentiviruses. J. Gen. Virol. 83: 1809-1829.
6. Cormier, E.G., and Dragic, T. 2002. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 76: 8953-8957.
7. Dragic, T. 2001. An overview of the determinants of CCR5 and CXCR4 co-receptor function. J. Gen. Virol. 82: 1807-1814.
8. Estes, J.D., Keele, B.F., Tenner-Racz, K., Racz, P., Redd, M.A., Thacker, T.C., Jiang, Y., Lloyd, M.J., Gartner, S., and Burton, G.F. 2002. Follicular dendritic cell-mediated up-regulation of CXCR4 expression on CD4 T cells and HIV pathogenesis. J. Immunol. 169: 2313-2322.
9. Foda, M., Harada, S., and Maeda, Y. 2001. Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity. Microbiol. Immunol. 45: 521-530.
10. Harada, S. 2002. Human immunodeficiency virus type 1 neutralization by a single molecule of V3-targeted antibody. Microbiol. Immunol. 46: 857-862.
11. Harada, S., Akaike, T., Yusa, K., and Maeda, Y. 2004. Adsorption and infectivity of human immunodeficiency virus type 1 are modified by the fluidity of the plasma membrane for multiple-site binding. Microbiol. Immunol. 48: 347-355.
12. Herrera, C., Spenlehauer, C., Fung, M.S., Burton, D.R., Beddows, S., and Moore, J.P. 2003. Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J. Virol. 77: 1084-1091.
13. Hoffman, T.L., and Doms, R.W. 1998. Chemokines and coreceptors in HIV/S1V-host interactions. AIDS 12 (suppl A): S17-S26.
14. Hu, Q., Trent, J.O., Tomaras, G.D., Wang, Z., Murray, J.L., Conolly, S.M., Navenot, J.M., Barry, A.P., Greenberg, M.L., and Peiper, S.C. 2000. Identification of Env determinants in V3 that influence the molecular anatomy of CCR5 utilization. J. Mol. Biol. 302: 359-375.
15. Jackson, N.A.C., Levi, M., Wahren, B., and Dimmock, N.J. 1999. Properties and mechanism of action of a 17 amino acid, V3 loop-specific microantibody that binds to and neutralizes human immunodeficiency virus type 1 virions. J. Gen. Virol. 80: 225-236.
16. Klasse, P.J., and Sattentau, Q.J. 2002. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 83: 2091-2108.
17. Kuhmann, S.E., Platt, E.J., Kozak, S.L., and Kabat, D. 2000. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J. Virol. 74: 7005-7015.
18. Loura, L.M., Fedorov, A., and Prieto, M. 2001. Fluid-fluid membrane microheterogeneity: a fluorescence resonance energy transfer study. Biophys. J. 80: 776-788.
19. Maeda, Y., Foda, M., Matsushita, S., and Harada, S. 2000. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1α. J. Virol. 74: 1787-1793.
20. Masuda, T., Matsushita, S., Kuroda, M.J., Kannagi, M., Takatsuki, K., and Harada, S. 1990. Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region. J. Immunol. 145: 3240-3246.
21. Matsushita, S., Robert-Guroff, M., Rusche, J., Koito, A., Hattori, T., Hoshino, H., Javaherian, K., Takatsuki, K., and Putney, S. 1988. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J. Virol. 62: 2107-2114.
22. Miller, E.D., Duus, K.M., Townsend, M., Yi, Y., Collman, R., Reitz, M., and Su, L. 2001. Human immunodeficiency virus type 1 IIIB selected for replication in vivo exhibits increased envelope glycoproteins in virions without alteration in coreceptor usage: separation on in vivo replication from macrophage tropism. J. Virol. 75: 8498-8506.
23. Mitsuya, H., Weinhold, K.J., Furman, P.A., St. Clair, M.H., Lehrman, S.N., Gallo, R.C., Bolognesi, D., Barry, D.W., and Broder, S. 1985. 3′-Azide-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 82: 7096-7100.
24. Picard, L., Simmons, G., Power, C.A., Meyer, A., Weiss, R.A., and Clapham, P.R. 1997. Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J. Virol. 71: 5003-5011.
25. Platt, E.J., Wehrly, K., Kuhmann, S.E., Chesebro, B., and Kabat, D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage tropic isolates of human immunodeficiency virus type 1. J. Virol. 72: 2855-2864.
26. Platt, E.J., Kuhmann, S.E., Rose, P.P., and Kabat, D. 2001. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfate region. J. Virol. 75: 12266-12278.
27. Poignard, P., Moulard, M., Golez, E., Vivona, V., Franti, M., Venturini, S., Wang, M., Parren, P.W.H.I., and Burton, D.R. 2003. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 77: 353-365.
28. Shimizu, N., Haraguchi, Y., Takeuchi, Y., Soda, Y., Kanbe, K., and Hoshino, H. 1999. Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein. Virology 259: 324-333.
29. Singer, S.J., and Nicolson, G.L. 1972. The fluid mosaic model of the structure of cell membrane. Science 175: 720-731.
30. Song, W., Yahara, S., Maeda, Y., Yusa, K., Tanaka, Y., and Harada, S. 2001. Enhanced infection of an X4 strain of HIV-1 due to capping and colocalization of CD4 and CXCR4 induced by capsianoside G, a diterpene glycoside. Biochem. Biophys. Res. Commun. 284: 423-429.
31. Tokunaga, K., Greenberg, M.L., Morse, M.A., Cumming, R.I., Lyerly, H.K., and Cullen, B.R. 2001. Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J. Virol. 75: 6776-6785.
32. Tamamura, T., Xu, Y., Hattori, T., Zhang, X., Arakaki, R., Kanbara, K., Omagari, A., Otaka, A., Ibuka, T., Yamamoto, N., Nakashima, H., and Fujii, N. 1998. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem. Biophys. Res. Commun. 253: 877-882.
33. Verrier, F., Borman, A.M., Brand, D., and Girard, M. 1999. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage. AIDS Res. Hum. Retrovir. 15: 731-743.
34. Wu, L., Paxton, W.A., Kassam, N., Ruffing, N., Rottman, J.B., Sullivan, N., Choe, H., Sodroski, J., Newman, W., Koup, R.A., and Mackay, C.R. 1997. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 185: 1681-1691.
35. Zhang, P.F., Bouma, P., Park, E.J., Margolick, J.B., Robinson, J.E., Zolla-Pazner, S., Flora, M.N., and Quinnan, G.V. 2002. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J. Virol. 76: 644-655.